Recombinant oncolytic virus and use thereof

Abstract

Provided are a recombinant oncolytic virus and a use thereof. The recombinant oncolytic virus includes an M protein and a cytokine encoded by an exogenous gene, wherein the M protein includes the following site mutations compared to an amino acid sequence as shown in SEQ ID NO 1: mutating of methionine at position 51 into arginine (M51R); mutating of valine at position 221 into phenylalanine (V221F); and mutating of serine at position 226 into arginine (S226R). The recombinant oncolytic viruses of the present application all have better infective ability and killing ability in vitro to abnormally proliferative (tumor) LLC cell, 4T1 cell, MC38 cell and Hela cell, and are not easy to eliminate in LLC cell, 4T1 cell, MC38 cell and Hela cell, greatly reducing the infective ability of the recombinant oncolytic viruses to normal cells.

Dependencies are inferred from the claim text.